Gilead Sciences, Inc.

LSE:0QYQ Stock Report

Market Cap: US$135.7b

Gilead Sciences Valuation

Is 0QYQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QYQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$247.23
Fair Value
56.1% undervalued intrinsic discount
26
Number of Analysts

Below Fair Value: 0QYQ ($108.65) is trading below our estimate of fair value ($247.23)

Significantly Below Fair Value: 0QYQ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QYQ?

Key metric: As 0QYQ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QYQ. This is calculated by dividing 0QYQ's market cap by their current earnings.
What is 0QYQ's PE Ratio?
PE Ratio22.5x
EarningsUS$5.97b
Market CapUS$135.73b

Price to Earnings Ratio vs Peers

How does 0QYQ's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QYQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.2x
GSK GSK
18.4x16.60%UK£58.0b
AZN AstraZeneca
28.1x14.55%UK£162.7b
HLN Haleon
25.8x6.91%UK£37.3b
AMGN Amgen
24.6x11.96%US$147.9b
0QYQ Gilead Sciences
22.5x11.08%US$135.7b

Price-To-Earnings vs Peers: 0QYQ is good value based on its Price-To-Earnings Ratio (22.5x) compared to the peer average (24.2x).

Price to Earnings Ratio vs Industry

How does 0QYQ's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0QYQ 22.5xIndustry Avg. 19.5xNo. of Companies6PE020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QYQ is expensive based on its Price-To-Earnings Ratio (22.5x) compared to the European Biotechs industry average (19.8x).

Price to Earnings Ratio vs Fair Ratio

What is 0QYQ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QYQ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.5x
Fair PE Ratio43.8x

Price-To-Earnings vs Fair Ratio: 0QYQ is good value based on its Price-To-Earnings Ratio (22.5x) compared to the estimated Fair Price-To-Earnings Ratio (43.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QYQ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$107.86
US$115.04
+6.65%
11.71%US$140.00US$92.00n/a26
May ’26US$104.09
US$114.17
+9.69%
12.09%US$140.00US$92.00n/a26
Apr ’26US$111.31
US$111.71
+0.36%
13.93%US$140.00US$82.00n/a25
Mar ’26US$113.37
US$108.15
-4.61%
11.31%US$130.00US$82.00n/a27
Feb ’26US$97.39
US$100.66
+3.37%
12.95%US$125.00US$73.00n/a27
Jan ’26US$91.89
US$98.92
+7.65%
12.62%US$125.00US$73.00n/a27
Dec ’25US$92.58
US$97.28
+5.08%
12.79%US$125.00US$69.00n/a28
Nov ’25US$89.55
US$87.94
-1.80%
13.89%US$123.00US$69.00n/a28
Oct ’25US$83.53
US$83.54
+0.016%
14.07%US$119.00US$68.50n/a27
Sep ’25US$78.91
US$83.43
+5.72%
14.13%US$119.00US$68.50n/a27
Aug ’25US$76.83
US$82.47
+7.34%
15.06%US$119.00US$67.00n/a27
Jul ’25US$68.56
US$82.97
+21.01%
14.22%US$119.00US$67.00n/a26
Jun ’25US$63.47
US$82.70
+30.29%
13.99%US$117.00US$67.00n/a26
May ’25US$65.01
US$83.69
+28.74%
12.99%US$117.00US$69.00US$104.0927
Apr ’25US$73.50
US$86.45
+17.62%
12.60%US$121.00US$69.00US$111.3126
Mar ’25US$72.46
US$87.86
+21.26%
12.55%US$121.00US$69.00US$113.3727
Feb ’25US$78.39
US$89.97
+14.77%
11.88%US$116.00US$69.00US$97.3927
Jan ’25US$80.76
US$90.15
+11.63%
11.94%US$116.00US$69.00US$91.8927
Dec ’24US$77.26
US$90.39
+17.00%
11.68%US$116.00US$71.00US$92.5827
Nov ’24US$80.20
US$90.95
+13.40%
11.16%US$116.00US$71.00US$89.5526
Oct ’24US$74.75
US$91.33
+22.18%
10.82%US$116.00US$71.00US$83.5326
Sep ’24US$76.73
US$91.75
+19.58%
10.30%US$116.00US$80.00US$78.9124
Aug ’24US$75.68
US$91.64
+21.09%
10.14%US$115.00US$77.00US$76.8325
Jul ’24US$76.87
US$92.60
+20.47%
9.84%US$115.00US$77.00US$68.5625
Jun ’24US$76.17
US$92.59
+21.55%
9.81%US$115.00US$77.00US$63.4725
May ’24US$81.36
US$92.56
+13.77%
8.83%US$115.00US$80.00US$65.0125
AnalystConsensusTarget
Consensus Narrative from 26 Analysts
US$116.03
Fair Value
6.4% undervalued intrinsic discount
26
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/21 03:53
End of Day Share Price 2025/05/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 71 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research